Literature DB >> 4606370

Comparison of azathioprine, cyclophosphamide, and gold in treatment of rheumatoid arthritis.

H L Currey, J Harris, R M Mason, J Woodland, T Beveridge, C J Roberts, D W Vere, A S Dixon, J Davies, B Owen-Smith.   

Abstract

Azathioprine, cyclophosphamide, and gold have been compared under double-blind conditions in the treatment of relatively early rheumatoid arthritis. Over 18 months the two "immunosuppressive" agents produced clinical improvement comparable to that achieved with gold, and they also facilitated a reduction in the dosage of corticosteroids and retarded radiological joint deterioration. Drug management was easiest with azathioprine. Cyclophosphamide was perhaps marginally the most effective drug but it produced azoospermia in males. If the long-term hazards of malignancy and mutagenesis prove to be acceptable then the anti-proliferative agents provide a useful alternative to gold therapy and can with advantage be given relatively early in the course of rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4606370      PMCID: PMC1611894          DOI: 10.1136/bmj.3.5934.763

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  9 in total

1.  Efficacy of immunosuppressive drugs in rheumatic diseases.

Authors:  A D Steinberg
Journal:  Arthritis Rheum       Date:  1973 Jan-Feb

2.  Development of reticulum cell sarcoma during cyclophosphamide therapy.

Authors:  H Tannenbaum; P H Schur
Journal:  Arthritis Rheum       Date:  1974 Jan-Feb

3.  Risk of cancer in renal-transplant recipients.

Authors:  R Hoover; J F Fraumeni
Journal:  Lancet       Date:  1973-07-14       Impact factor: 79.321

4.  Sterility and testicular atrophy related to cyclophosphamide therapy.

Authors:  K F Fairley; J U Barrie; W Johnson
Journal:  Lancet       Date:  1972-03-11       Impact factor: 79.321

5.  Immunoregulation, oncogenic viruses, and malignant lymphomas.

Authors:  R S Schwartz
Journal:  Lancet       Date:  1972-06-10       Impact factor: 79.321

6.  Cyclophosphamide and reproductive function.

Authors:  R Kumar; J D Biggart; J McEvoy; M G McGeown
Journal:  Lancet       Date:  1972-06-03       Impact factor: 79.321

7.  De novo malignant tumors in organ transplant recipients.

Authors:  I Penn; C G Halgrimson; T E Starzl
Journal:  Transplant Proc       Date:  1971-03       Impact factor: 1.066

8.  Immunosuppressive drugs in rheumatoid arthritis.

Authors:  A S Dixon; D J Lindsay; E M Collins
Journal:  Br Med J       Date:  1971-02-20

9.  Treatment of patients with systemic lupus erythematosus including nephritis with chlorambucil.

Authors:  M L Snaith; J M Holt; D O Oliver; M S Dunnill; W Halley; A C Stephenson
Journal:  Br Med J       Date:  1973-04-28
  9 in total
  34 in total

1.  In rheumatoid arthritis is compliance in physicians more of a problem than compliance in patients?

Authors:  R J Rooney; W W Buchanan
Journal:  Clin Rheumatol       Date:  1990-09       Impact factor: 2.980

Review 2.  Treatment of severe rheumatoid arthritis.

Authors:  V Wright
Journal:  Br Med J (Clin Res Ed)       Date:  1986-02-15

Review 3.  New approaches to the treatment of rheumatoid arthritis.

Authors:  P A Miescher; Y P Huang; R H Zubler
Journal:  Springer Semin Immunopathol       Date:  1988

4.  Azathioprine hypersensitivity manifesting as acute focal hepatocellular necrosis.

Authors:  C Cooper; D W Cotton; N Minihane; M I Cawley
Journal:  J R Soc Med       Date:  1986-03       Impact factor: 5.344

Review 5.  Joint damage in rheumatoid arthritis: radiological assessments and the effects of anti-rheumatic drugs.

Authors:  D L Scott; P A Bacon
Journal:  Rheumatol Int       Date:  1985       Impact factor: 2.631

6.  Regulation of secondary antibody responses in rodents. I. Potentiation of IgG production by cyclophosphamide.

Authors:  R F Gagnon; I C MacLennan
Journal:  Clin Exp Immunol       Date:  1979-07       Impact factor: 4.330

7.  Investigations on the influence of cyclophosphamide, gold sodium thiomalate and D-penicillamine on nystatin oedema and adjuvant arthritis.

Authors:  E Arrigoni-Martelld; E Bramm
Journal:  Agents Actions       Date:  1975-08

8.  Azathioprine in 50 rheumatoid arthritic patients intolerant or unresponsive to gold or penicillamine.

Authors:  E A Jenkins; B M Ansell; M A Hall; S P Liyanage
Journal:  Clin Rheumatol       Date:  1985-09       Impact factor: 2.980

9.  Serum biochemistry in relation to the action of azathioprine in rheumatoid arthritis.

Authors:  J S Dixon; H A Bird; N G Sitton; M E Pickup; P A Leatham; V Wright
Journal:  Agents Actions       Date:  1983-06

10.  Disparity between clinical and immune responses in a controlled trial of azathioprine in rheumatoid arthritis.

Authors:  K M GOEBEL; R Janzen; K Joseph; U Börngen
Journal:  Eur J Clin Pharmacol       Date:  1976-03-22       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.